Skip to content

Abivax

  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • Overview
    • Patients
    • ABX464 for UC
    • ABX464 for Crohn’s
    • ABX464 for RA
    • ABX464 for COVID-19
    • ABX464 for HIV
    • ABX196 for HCC
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Overview
    • Share Price
    • Investor Documents
    • Annual General Meeting
  • Contact Us
  • Career
Search
  • EN
  • FR
  • DE

News & Events

Press Coverage

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

BioCentury

May 3, 2017

ABIVAX DOUBLES ON HIV RESERVOIR READOUT

LabioTech

May 3, 2017

French HIV Cure Reduces Viral Reservoirs for the First Time Ever

Reuters

April 4, 2017

Abivax initiates clinical trial (ABX464-005) to evaluate effect of ABX464 on HIV-reservoirs in HIV patients

The Pharma Letter

March 5, 2017

Market reaction reflects interest in Abivax HIV breakthrough

Reuters

January 9, 2017

ABIVAX to receive 8.4 mln euro grant from Bpifrance

  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
© 2021 All rights reserved by ABIVAX | Website created by DIGITAL VALLEE Privacy and Terms of Use
  • About Us
    • Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • Overview
    • Publications
  • Pipeline
    • ABX464 for UC
    • ABX464 for HIV
    • ABX196 for HCC
    • ABX544 for Ebola Virus
  • News & Events
    • Press Releases
    • Press Coverage
    • Upcoming Events
  • Investors
    • Share Profile
    • Share Price
    • Investor Documents
    • Analysts
    • Annual General Meeting
    • UEG Week 2019
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn
  • Follow us on YouTube
  • Follow us on Google+